DOCSLIB.ORG

Androgen Receptor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Androgen Receptor DOXORUBICIN HYDROCHLORIDE NICLOSAMIDE TNF-alpha Cellular tumor antigen p53Tubulin FLUOROURACIL DAUNORUBICIN HYDROCHLORIDE Hypoxia-inducible factor 1 alpha PACLITAXEL Tubulin beta chain Tubulin alpha chain TOPOTECAN HYDROCHLORIDE Muscleblind-like protein 1 COLCHICINE DIGOXIN Beta-lactamase AmpCFlap endonuclease 1 Ataxin-2 Paired box protein Pax-8 ORF 73 Anthrax lethal factor DIPHENADIONE 6-phospho-1-fructokinasePODOFILOXVINBLASTINE SULFATE Isocitrate dehydrogenase [NADP] cytoplasmicProtein S100-A4 Huntingtin Signal transducer and activator of transcription 6 DNAThioredoxin polymerase reductase beta14-3-3 1- cytoplasmic protein gamma HSP40- subfamily A- putative Menin/Histone-lysineCruzipain N-methyltransferaseNuclear MLL receptor VINCRISTINEsubfamily 0 group SULFATE B NIFENAZONEmember 1 Sodium/potassium-transporting ATPase AZELASTINEMIDAZOLAM HYDROCHLORIDE HYDROCHLORIDE MITOXANTRONE DIHYDROCHLORIDE Solute carrier organic anion transporter Endonucleasefamily memberBISACODYL 4 4C1 Caspase-1 ATPase family AAA domain-containing protein 5 BreastMETHOTREXATE cancer type 1 susceptibility protein TRIFLURIDINE Sodium/potassium-transporting ATPase alpha-1 chain TRIAMTERENECYTARABINE Transcription factor SKN7 AZACITIDINEDEQUALINIUMTRIFLUPROMAZINE CHLORIDEMothersCLADRIBINE against decapentaplegicEPIRUBICIN homolog HYDROCHLORIDE 3 Pteridine reductase 1 Latent membrane protein 1 MELATONIN Arachidonate 15-lipoxygenase- type II Nuclear receptor coactivator 3 DIGITOXIN Retinoid X receptor alpha AMSACRINE IRINOTECAN HYDROCHLORIDE HYDRATE MEBENDAZOLEBacterial DNA-directed RNABromodomain polymeraseVINBURNINE adjacentTubulin to zinc fingerbeta-3 domain chain protein 2B TAR DNA-binding protein 43 AZITHROMYCINHepatitis C virus NS3 protease/helicase Ubiquitin carboxyl-terminal hydrolase 2 Small conductance calcium-activated potassiumFrizzled-1 channel protein 3 Histone-lysine N-methyltransferase MLL DECITABINE THIOGUANINEThymidylate synthase SmallNuclear conductance receptor calcium-activatedROR-gamma potassiumVINPOCETINE channel LANATOSIDE C Beta tubulin Thyroid stimulating hormone receptor Transcriptional regulator ERG NeuropeptideMelatonin S receptor receptor 1B MELPHALANPENTAMIDINE DIISETHIONATEThymidineGlucagon-like kinase Cholecystokinin peptide 1 receptor A receptor Prelamin-A/C BENZTROPINEDNA dC->dU-editing MESYLATE enzyme APOBEC-3G Caspase-7 4'-phosphopantetheinylAberrantDNA topoisomerase vpr protein II transferasealphaATOMOXETINE ffp HYDROCHLORIDEChromobox protein Serine/threonine-proteinhomolog 1 kinase PLK1 MelatoninQuinoneMelatonin receptorMelatonin reductase receptor receptor 2 1A 1C SEMAGLUTIDEDNA topoisomeraseHeat I shock protein HSP90 CREB-binding protein NORTRIPTYLINE HYDROCHLORIDE HistoneSerine/threonine-protein acetyltransferaseLIRAGLUTIDEPeptidyl-prolyl GCN5 cis-trans kinase isomerase mTOR NIMA-interacting 1 Tubulin polymerization-promoting protein DNABloom topoisomerase syndrome proteinII EXENATIDE NITAZOXANIDEORPHENADRINE (CHLORIDE) Microtubule-associated protein tau Transcription factor AP-1 Deoxycytidine kinase Folate transporter 1 Histone-lysineCARMUSTINE N-methyltransferase- H3 lysine-9 specific 3 MAPROTILINEBifunctional dihydrofolate reductase-thymidylate synthase Geminin LIPOIC ACID, ALPHAIDARUBICINEVEROLIMUS HYDROCHLORIDEProton-coupled folate transporter Kelch-likeTEMSIROLIMUS ECH-associatedINDOCYANINE protein 1 Lysine-specific GREEN SODIUM demethylase 4A AMITRIPTYLINE HYDROCHLORIDEProto-oncogeneCalmodulin-domain c-JUN protein kinaseEndoplasmicHYDROQUINONE 1 reticulum-associated amyloid beta-peptide-binding protein CARBIMAZOLE Solute carrier organic anionIntegrin transporter alpha-V/beta-3 family memberAlpha-synuclein 1A3 Aryl hydrocarbon receptorAMINEPTINEMESORIDAZINEMETRONIDAZOLEOXYPHENBUTAZONE DOXIFLURIDINEBISOPROLOLUDP-galactopyranose mutase RALTITREXED UBIDECARENONE FLOXURIDINE TRIMETHOPRIM Vitamin D receptorButyrylcholinesteraseThrombopoietinNICORANDIL BROMOCRIPTINE MESYLATE SORAFENIB TOSYLATE HemoglobinMOSAPRAMINESODIUM beta chain SELENITE LactoperoxidaseDNA-(apurinic or apyrimidinic site) lyase Dihydrofolate reductase type 1DNA polymerase eta SurvivalAZATHIOPRINE motorMINOCYCLINE neuron protein HYDROCHLORIDEMONTELUKASTHypoxanthine-guanine SODIUM phosphoribosyltransferaseDULOXETINE HYDROCHLORIDE DACTINOMYCINCARBOPLATIN MITOMYCIN SUMO-activatingLethal(3)malignant enzyme brainDihydrofolate tumor-like protein reductase 1 RIBAVIRINNELFINAVIRCAMPHORVANCOMYCIN MESYLATE HYDROCHLORIDEPHENELZINEAMIODARONE SULFATE HYDROCHLORIDENonstructural proteinFOLIC 1 ACIDPutative fructose-1-6-bisphosphate aldolase BIFEMELANESignal transducer andMYCOPHENOLIC activator of transcription ACID 3 ICLAPRIM Thyroid hormone receptorAldehyde beta-1 dehydrogenaseIMIPRAMINE 1A1 HYDROCHLORIDEDYDROGESTERONEUbiquitin carboxyl-terminalDual specificityDNA hydrolaserepair tyrosine-phosphorylation-regulated protein 1 RAD52Folate homolog receptor alpha kinase 1A ThioredoxinDIDANOSINE glutathionePeripheral reductase myelin protein 22 HeatStreptokinase shock factor A proteinFolate 1 receptor beta Arachidonate 12-lipoxygenaseCALCIPOTRIENE DIMETACRINE CHLORAMBUCIL TAURINEDESERPIDINENiemann-Pick C1 proteinDNA-3-methyladenineApoptosis glycosylaseregulator Bcl-2 PutativeSolute uncharacterized carrierTELMISARTAN DEXTROTHYROXINEorganic protein anion transporter family NuclearmemberETAFENONEMISOPROSTOLCLOFAZIMINE 1C1 factor erythroid 2-relatedPYRIMETHAMINE factorDNA 2 polymerase kappaDOXYCYCLINE HYCLATE BETAMETHASONE TEMOPORFIN78 kDa glucose-regulated protein Growth factor receptor-bound protein 2 FEPRAZONE LuciferaseApoptosis regulator BENZBROMARONEBcl-X DISULFIRAM MethionineLEFLUNOMIDE aminopeptidase 2 LIOTHYRONINERas-related SODIUM protein Rab-9A ATP-dependent DNA helicase Q1 Peroxisome proliferator-activatedOXYQUINOLINEDNA receptor polymerase gamma III THIRAMVITAMINGLYCERIN E Large T antigenBeta-hexosaminidase subunit beta GuanineSODIUM nucleotide-binding LAURYL SULFATE protein G(s)- subunit alpha Beta-N-acetyl-D-hexosaminidase-A/BInosine-5'-monophosphateTIAPROFENIC dehydrogenase ACID 1 ISOETHARINECerebroside-sulfatase CLOFARABINELABETALOLBUTOCONAZOLE HYDROCHLORIDE NITRATE NAVITOCLAX FELODIPINEM-phase phosphoprotein VINORELBIN8 DITARTRATE ETRETINATE THIOTEPA DESLANOSIDEInosine-5'-monophosphate dehydrogenaseBcl2-antagonist 2 of cell death (BAD) Angiotensin-converting enzyme RapBENZIODARONE guanine nucleotideBARDOXOLONE exchange factor 3METHYLRap guanineEnvelope nucleotide glycoproteinTANESPIMYCIN exchange factorgp160 4 Polypyrimidine tract-binding Monoglycerideprotein 1 CINCHOPHEN lipaseBENAZEPRILBaculoviral HYDROCHLORIDE IAP repeat-containingTOLCAPONERegulator protein of 5G-protein signaling 4 GABA receptor subunit Parathyroid hormone receptor OBETICHOLIC ACID Runt-relatedATACIGUAT transcription factor 1/Core-binding factorPeroxisome subunitTERIPARATIDE betaproliferator-activatedProtein receptor RecA gamma/Nuclear receptor corepressor 2 Bile acid receptorC-C FXRchemokineGAMOLENICSteroid receptor 5-alpha-reductase type ACID 4 PENTAERYTHRITOL 2 DNA TETRANITRATE polymeraseSURAMIN iota HEXASODIUMHeatHeat shock shock protein protein HSP 75 kDa-90 (HSP82) mitochondrial C-CFUROSEMIDE chemokinePeroxisome receptor type 2 proliferator-activatedTROLAMINE ACITRETIN receptorNuclearCatecholMANNITOL factorMOXIFLOXACIN O-methyltransferasedelta NF-kappa-B HYDROCHLORIDE p105Solute subunit carrier family 22 member 12 Enoyl-acyl carrier reductaseLONIDAMINEMYCOPHENOLATETRIPTORELIN MOFETIL UDP-glucuronosyltransferaseESTRAMUSTINEHeat shock Replicativeprotein 1-9 90 beta DNA helicase Arachidonate 5-lipoxygenasePATUPILONEICOSAPENT MEROPENEMUREA Transient receptorNuclear potentialMENTHOL receptor cation channelsubfamily subfamilyEnoyl-acyl-carrier 1 groupTRICLOSAN M I membermember protein 28 reductase CISPLATIN ENTACAPONELysosomal alpha-glucosidase BAZEDOXIFENEROSIGLITAZONE ACETATEOXAPROZIN MALEATETRIAMCINOLONEANECORTAVE DIACETATE ACETATE Leukotriene B4 receptor 1 OCTANOIC ACIDLOTEPREDNOLHeat ETABONATE shock proteinHeat HSPGANETESPIB shock 90-alpha protein HSP 90-beta 15-hydroxyprostaglandin dehydrogenase [NAD+]PIPERINEEnoyl-ACPMETHYLENE NABUMETONEreductase BLUE CHLORIDETRILOSTANENORETHINDRONE HYDRATEBETAMETHASONESALICYLAMIDEHYDROXYPROGESTERONEVALRUBICIN ACETATE VALERATE CAPROATE Lipoxygenase TAMOXIFEN CITRATERXR alpha/PPAR gamma MK-2206 Solute carrier family 22 member 8 NORDIHYDROGUAIARETICEnoyl-[acyl-carrier-protein] ACID reductase [NADPH] HALOBETASOLPRALATREXATEWerner syndrome PROPIONATE ATP-dependentINDOPROFEN helicase Seed lipoxygenase-1Carbonyl reductasePIOGLITAZONE [NADPH] HYDROCHLORIDE 1 EXEMESTANEHYDROCORTISONE SODIUM SUCCINATE FLUOCINOLONEATALUREN ACETONIDE Interleukin-8 receptors- CXCR1/CXCR2 Peroxisome proliferator-activatedAldose reductase receptorLuciferin alpha 4-monooxygenase GALETERONEGLIMEPIRIDEMAP kinase ERK2 ALEGLITAZAR SULFADIAZINE, SILVERENOBOSARM 11-beta-hydroxysteroid dehydrogenase 2 Heat shock protein CHLOROTRIANISENEbeta-1QuinoneAMLEXANOX reductase 1)ESTRAMUSTINENANDROLONETyrosyl-DNA PHOSPHATE DECANOATE phosphodiesterase SODIUM 1 DEXIBUPROFEN TEDIZOLID PHOSPHATEEnoyl-[acyl-carrier-protein]Androgen reductase [NADH] ReceptorProtein-tyrosine phosphataseNAPROXEN 2C ARTEMISININDEXTROAMPHETAMINEInterleukin-8 UNOPROSTONERIFABUTIN11-beta-hydroxysteroid ISOPROPYL dehydrogenase 1 Cytochrome P450 2B6 DEXAMETHASONEHYDROCORTISONEDICUMAROLNILUTAMIDE SODIUM PHOSPHATEENOXOLONEProstaglandin G/H synthase (cyclooxygenase) Monoamine oxidase A FOSDAGROCORAT GEMCITABINEPERICIAZINE HYDROCHLORIDE SELEGILINEEstrogen-related HYDROCHLORIDE receptor beta POLIDOCANOL DOXERCALCIFEROLMETILDIGOXIN
Load more

Recommended publications
  • Erteberel (LY500307) Product Data Sheet
    Product Name: Erteberel (LY500307) Revision Date: 01/10/2021 Product Data Sheet Erteberel (LY500307) Cat. No.: B1518 CAS No.: 533884-09-2 Formula: C18H18O3 M.Wt: 282.33 Synonyms: Target: Endocrinology and Hormones Pathway: Estrogen/progestogen Receptor Storage: Store at -20°C Solvent & Solubility insoluble in H2O; ≥14.1 mg/mL in DMSO; ≥48.3 mg/mL in EtOH Mass Solvent 1mg 5mg 10mg Preparing Concentration In Vitro Stock Solutions 1 mM 3.5420 mL 17.7098 mL 35.4195 mL 5 mM 0.7084 mL 3.5420 mL 7.0839 mL 10 mM 0.3542 mL 1.7710 mL 3.5420 mL Please refer to the solubility information to select the appropriate solvent. Biological Activity Shortsummary ERβ agonist, potent and selective IC₅₀ & Target Cell Viability Assay Cell Line: Human prostate cancer cell line (PC-3 cells) Preparation method： The solubility of this compound in DMSO is >10 mM. General tips for obtaining In Vitro a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months. Reacting conditions: N/A 1 | www.apexbt.com Applications: Erteberel showed potent and selective binding affinity for ERβ with EC50 value of 0.66 nM [1]. Animal experiment Animal models: Male and female rat fertility and rat and rabbit embryo-fetal development model Dosage form: 0.03 to 10 mg/kg/day for rats, or 1 to 25 mg/kg/day for rabbits, oral gavage, for 2 or 10 weeks Applications: There were no-observed adverse effect levels following LY500307 In Vivo administration of 1 mg/kg/day for male rat fertility, 0.3 mg/kg/day for female rat fertility and embryo-fetal development, and 25 mg/kg/day for rabbit embryo-fetal development [2].
    [Show full text]
  • ( 12 ) United States Patent
    US010231994B2 (12 ) United States Patent (10 ) Patent No. : US 10 , 231, 994 B2 Kuklinski et al. (45 ) Date of Patent: Mar. 19 , 2019 ( 54 ) SELENIUM -CONTAINING COMPOSITIONS 5 ,470 , 880 A 11 / 1995 Yu et al. 5 ,512 , 200 A 4 / 1996 Garcia AND USES THEREOF 5 , 536 ,497 A 7 / 1996 Evans et al . 6 , 069 , 152 A 5 / 2000 Schaus et al. (71 ) Applicant : SELO MEDICAL GMBH , Unternberg 6 , 114 , 348 A 9 / 2000 Weber et al. (AT ) 6 , 120 ,758 A 9 / 2000 Siddiqui et al . 6 , 133 , 237 A 10 / 2000 Noll et al. 6 , 277 , 835 B1 8 / 2001 Brown (72 ) Inventors : Bodo Kuklinski, Rostock (DE ) ; Peter 6 , 391 , 323 B1 5 / 2002 Carnevali Kössler , Mariapfarr ( AT ); Norbert 2003 / 0180387 AL 9 / 2003 Kossler et al . Fuchs , Mariapfarr (AT ) 2004 /0265268 A1 * 12 /2004 Jain . A61K 8 /64 424 /85 . 1 (73 ) Assignee : SELO MEDICAL GMBH , Unternberg 2005 /0048134 AL 3 /2005 Kuklinski et al. ( AT ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer , the term of this patent is extended or adjusted under 35 DE 3408362 9 / 1984 DE 43 20 694 1 / 1995 U . S . C . 154 (b ) by 0 days . DE 43 35 441 4 / 1995 DE 44 13 839 10 / 1995 (21 ) Appl. No. : 15 / 725 , 455 EP 0 000 670 2 / 1979 EP 0 750 911 1 / 1997 ( 22 ) Filed : Oct. 5 , 2017 EP 0 913 155 5 / 1999 FR 2 779 720 12 / 1999 GB 2323030 9 / 1998 (65 ) Prior Publication Data WO WO 00 / 12101 3 /2000 US 2018 / 0028559 A1 Feb .
    [Show full text]
  • Oral Ambroxol Increases Brain Glucocerebrosidase Activity in a Nonhuman Primate
    Received: 17 November 2016 | Revised: 24 January 2017 | Accepted: 12 February 2017 DOI 10.1002/syn.21967 SHORT COMMUNICATION Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate Anna Migdalska-Richards1 | Wai Kin D. Ko2 | Qin Li2,3 | Erwan Bezard2,3,4,5 | Anthony H. V. Schapira1 1Department of Clinical Neurosciences, Institute of Neurology, University College Abstract London, NW3 2PF, United Kingdom Mutations in the glucocerebrosidase 1 (GBA1) gene are related to both Parkinson disease (PD) and 2Motac Neuroscience, Manchester, United Gaucher disease (GD). In both cases, the condition is associated with deficiency of glucocerebrosi- Kingdom dase (GCase), the enzyme encoded by GBA1. Ambroxol is a small molecule chaperone that has 3 Institute of Laboratory Animal Sciences, been shown in mice to cross the blood-brain barrier, increase GCase activity and reduce alpha- China Academy of Medical Sciences, Beijing synuclein protein levels. In this study, we analyze the effect of ambroxol treatment on GCase City, People’s Republic of China activity in healthy nonhuman primates. We show that daily administration of ambroxol results in 4University de Bordeaux, Institut des Maladies Neurodeg en eratives, UMR 5293, increased brain GCase activity. Our work further indicates that ambroxol should be investigated as Bordeaux F-33000, France a novel therapy for both PD and neuronopathic GD in humans. 5CNRS, Institut des Maladies Neurodeg en eratives, UMR 5293, Bordeaux F-33000, France KEYWORDS Correspondence ambroxol, glucocerebrosidase,
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies
    International Journal of Molecular Sciences Review GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies Andrés Felipe Leal 1 , Eliana Benincore-Flórez 1, Daniela Solano-Galarza 1, Rafael Guillermo Garzón Jaramillo 1 , Olga Yaneth Echeverri-Peña 1, Diego A. Suarez 1,2, Carlos Javier Alméciga-Díaz 1,* and Angela Johana Espejo-Mojica 1,* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia; [email protected] (A.F.L.); [email protected] (E.B.-F.); [email protected] (D.S.-G.); [email protected] (R.G.G.J.); [email protected] (O.Y.E.-P.); [email protected] (D.A.S.) 2 Faculty of Medicine, Universidad Nacional de Colombia, Bogotá 110231, Colombia * Correspondence: [email protected] (C.J.A.-D.); [email protected] (A.J.E.-M.); Tel.: +57-1-3208320 (ext. 4140) (C.J.A.-D.); +57-1-3208320 (ext. 4099) (A.J.E.-M.) Received: 6 July 2020; Accepted: 7 August 2020; Published: 27 August 2020 Abstract: GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay–Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic of GM2 gangliosidoses patients that include neurodevelopment alterations, neuroinflammation, and neuronal apoptosis. Currently, there is not approved therapy for GM2 gangliosidoses, but different therapeutic strategies have been studied including hematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction therapy, pharmacological chaperones, and gene therapy.
    [Show full text]
  • Genetics and Epigenetics in Parkinson´S Disease
    Genetics and epigenetics in Parkinson´s disease. Luis Navarro Sánchez. Thesis supervisor: Jordi Pérez Tur. Unitat de Genètica Molecular, Institut de Biomedicina de València, CSIC. Doctoral studies: Biotechnology. Facultat de Ciències Biològiques, Universitat de València. Tras preguntas y más preguntas y miedo y nervios y ansiedad y más ansiedad y bloqueos y periodos depresivos y tristeza y mucha, pero mucha, mierda… acabas. Tarde y reventado, pero acabas. Y lo único que quieres es pasar página y que esto no te pase más nunca. ¿Y? Pues que te surgen más preguntas y más miedo y más nervios…. Y te das cuenta de que vives en un puto bucle científico que se está comiendo tu vida. ¿Y? No lo sé, estoy en ello. Terapia y medicación, supongo. Aunque la autodestrucción y los realities son muy apetecibles. En primer lugar, las formalidades. Gracias Jordi por dejarme que trabajara en la UGM. A estas alturas, creo que los dos nos habremos planteado muchas veces si fue una buena decisión, pero ya da igual. A continuación, el momento pasteleo, aunque si no sé dar un abrazo, no penséis que esto me va a salir fluido. Y menos aún, estando sobrio. Y que no se me enfade nadie si no he puesto su nombre o si no he escrito un parrafazo lacrimógeno y azucarado exaltando la belleza de nuestra relación. Si dejo que leas esto, significa que también eres importante para mí. Lo mejor de todo este tiempo sois, de calle, vosotros y vosotras: Bea, Carolina, Eva, Fer, LauraA, LauraG, María, Marta, Pili, Silvia, Vicente/Andreu y VicenteH.
    [Show full text]
  • Guthrie Cdna Resource Center
    cDNA Resource Center cDNA Resource Center Catalog cDNA Resource Center Missouri University of Science and Technology 400 W 11th Rolla, MO 65409 TEL: (573) 341-7610 FAX: (573) 341-7609 EMAIL: [email protected] www.cdna.org September, 2008 1 cDNA Resource Center Visit our web site for product updates 2 cDNA Resource Center The cDNA Resource Center The cDNA Resource Center is a service provided by the faculty of the Department of Biological Sciences of Missouri University of Science and Technology. The purpose of the cDNA Resource Center is to further scientific investigation by providing cDNA clones of human proteins involved in signal transduction processes. This is achieved by providing high quality clones for important signaling proteins in a timely manner. By high quality, we mean that the clones are • Sequence verified • Propagated in a versatile vector useful in bacterial and mammalian systems • Free of extraneous 3' and 5' untranslated regions • Expression verified (in most cases) by coupled in vitro transcription/translation assays • Available in wild-type, epitope-tagged and common mutant forms (e.g., constitutively- active or dominant negative) By timely, we mean that the clones are • Usually shipped within a day from when you place your order. Clones can be ordered from our web pages, by FAX or by phone. Within the United States, clones are shipped by overnight courier (FedEx); international orders are shipped International Priority (FedEx). The clones are supplied for research purposes only. Details on use of the material are included on the Material Transfer Agreement (page 3). Clones are distributed by agreement in Invitrogen's pcDNA3.1+ vector.
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 24, No. 4, 2010 World Health Organization WHO Drug Information Contents WHO Prequalification Sitaxentan: worldwide withdrawal 307 Programmes Sibutramine: suspension of sales 307 Sibutramine-containing medicines: WHO Prequalification of Medicines withdrawal 308 Programme: survey of service Testosterone transdermal patch: quality provided to manufacturers 293 withdrawal of extension of WHO initiates pilot prequalification of indication application 308 active pharmaceutical ingredients 297 Aliskiren/valsartan: withdrawal of New on-line database for WHO marketing authorization application 308 prequalified vaccines 298 Mometasone furoate/formoterol fumarate: withdrawal of marketing Safety and Efficacy Issues authorization application 309 EMA and US FDA extend confidentiality H1N1 influenza vaccine: narcolepsy 299 arrangements indefinitely 309 Statins: interstitial lung disease 299 Tocilizumab: risk of fatal anaphylaxis 300 Recent Publications, Pioglitazone: potential bladder cancer 301 Information and Events Angiotensin receptor blockers and US Government to share patents with cancer: safety review 301 Medicines Patent Pool 310 GnRH agonists, diabetes and cardio- Clinical trials and global medicines vascular disease 301 development 310 Gadolinium-based contrast agents: Evaluation of future nanomedicines 311 kidney dysfunction 302 Reporting on opioid inaccessibility 311 Lamotrigine: aseptic meningitis Tinzaparin sodium: renal Impairment in elderly 303 Consultation Documents Tamoxifen: drug interactions involving The
    [Show full text]
  • Hepatotoxicity-Induced by the Therapeutic Dose of Acetaminophen and the Ameliorative Effect of Oral Co-Administration of Selenium/ Tribulus Terrestris Extract in Rats
    Int. J. Morphol., 38(5):1444-1454, 2020. Hepatotoxicity-Induced by the Therapeutic Dose of Acetaminophen and the Ameliorative Effect of Oral Co-administration of Selenium/ Tribulus terrestris Extract in Rats Hepatotoxicidad Inducida por la Dosis Terapéutica de Acetaminofén y el Efecto de Mejora de la Administración Conjunta de Extracto de Selenio Tribulus terrestris en Ratas Amin A. Al-Doaiss1,2 AL-DOAISS, A. A. Hepatotoxicity-induced by the therapeutic dose of acetaminophen and the ameliorative effect of oral co-administration of selenium / Tribulus terrestris extract in rats. Int. J. Morphol., 38(5):1444-1454, 2020. SUMMARY: Over dose or long-term clinical use of therapeutic doses of acetaminophen (APAP) causes hepatotoxicity. Various strategies attempted to ameliorate APAP-hepatotoxicity have been found to be unsuitable for clinical practice. This study was aimed to illustrate the histopathological changes induced by therapeutic dose of APAP and investigate the hepatoprotective role of oral co- administration of selenium/ Tribulus terrestris (TT) extract concurrently against hepatotoxicity induced by APAP in rats. Fifty-four healthy male albino Wistar rats were randomized into nine groups (G1–G9) of six rats each, and administered with APAP and TT orally for 30 days as follows: Control (2ml normal saline), APAP (470 mg/kg), APAP (470 mg/kg) + selenium (2 mg/kg), APAP (470 mg/kg) + TT (98 mg/kg), APAP (470 mg/kg) + selenium (2mg/kg) + TT (98 mg/kg), APAP (470 mg/kg) + silymarin (200 mg/kg), selenium (2 mg/ kg), TT (98 mg/kg) and silymarin (200 mg/kg) groups. The results demonstrated that exposure of rats to therapeutic dose of APAP for 30 days caused significant histopathological changes parallel to elevated blood chemistry parameters.
    [Show full text]
  • Confidential: for Review Only
    BMJ Confidential: For Review Only The risk of fall and fracture with the initiation of a prostate - selective alpha antagonist Journal: BMJ Manuscript ID: BMJ.2015.028205 Article Type: Research BMJ Journal: BMJ Date Submitted by the Author: 17-Jul-2015 Complete List of Authors: Welk, Blayne; Western University, McArthur, Eric; Institute for Clinical Evaluative Sciences,, Fraser, Lisa-Ann; Western University, Medicine Hayward, Jade; Institute for Clinical Evaluative Sciences,, Dixon, Stephanie; Institute for Clinical Evaluative Sciences,, Hwang, Joseph; Case Western Reserve University School of Medicine, Ordon, Michael; University of Toronto, Surgery (Urology) Keywords: BPH, Fall, Fracture, Alpha antgonist https://mc.manuscriptcentral.com/bmj Page 1 of 45 BMJ 1 2 The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist 3 4 1,2,3 2 4 2 5 Blayne Welk MD MSc , Eric McArthur MSc , Lisa-Ann Fraser MD MSc , Jade Hayward , 6 Stephanie Dixon MSc PhD 2,3 , Y. Joseph Hwang MSc 5, Michael Ordon MD MSc 6 7 8 1 DepartmentConfidential: of Surgery, Western University, For London Review, Ontario, Canada Only 9 2 Institute for Clinical Evaluative Sciences, London, Ontario, Canada 10 11 3 Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada 12 4 Department of Medicine, Western University, London, Ontario 13 5 MD Candidate, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA 14 6 Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada 15 16 17 Correspondence: 18 Blayne Welk, MD MSc 19 Assistant Professor, Division of Urology and Epidemiology and Biostatistics 20 Western University 21 Room B4-667 22 23 St Joseph's Health Care 24 268 Grosvenor Street London ON N6A 4V2 25 Telephone: 519 646-6367 | Fax: 519 646-6037 26 [email protected] 27 28 29 Addresses: 30 Mr McArthur: [email protected] 31 LHSC – Victoria Hospital 32 ELL-101, 800 Commissioners Rd.
    [Show full text]
  • TE INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub
    US 20200187851A1TE INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No .: US 2020/0187851 A1 Offenbacher et al. (43 ) Pub . Date : Jun . 18 , 2020 ( 54 ) PERIODONTAL DISEASE STRATIFICATION (52 ) U.S. CI. AND USES THEREOF CPC A61B 5/4552 (2013.01 ) ; G16H 20/10 ( 71) Applicant: The University of North Carolina at ( 2018.01) ; A61B 5/7275 ( 2013.01) ; A61B Chapel Hill , Chapel Hill , NC (US ) 5/7264 ( 2013.01 ) ( 72 ) Inventors: Steven Offenbacher, Chapel Hill , NC (US ) ; Thiago Morelli , Durham , NC ( 57 ) ABSTRACT (US ) ; Kevin Lee Moss, Graham , NC ( US ) ; James Douglas Beck , Chapel Described herein are methods of classifying periodontal Hill , NC (US ) patients and individual teeth . For example , disclosed is a method of diagnosing periodontal disease and / or risk of ( 21) Appl. No .: 16 /713,874 tooth loss in a subject that involves classifying teeth into one of 7 classes of periodontal disease. The method can include ( 22 ) Filed : Dec. 13 , 2019 the step of performing a dental examination on a patient and Related U.S. Application Data determining a periodontal profile class ( PPC ) . The method can further include the step of determining for each tooth a ( 60 ) Provisional application No.62 / 780,675 , filed on Dec. Tooth Profile Class ( TPC ) . The PPC and TPC can be used 17 , 2018 together to generate a composite risk score for an individual, which is referred to herein as the Index of Periodontal Risk Publication Classification ( IPR ) . In some embodiments , each stage of the disclosed (51 ) Int. Cl. PPC system is characterized by unique single nucleotide A61B 5/00 ( 2006.01 ) polymorphisms (SNPs ) associated with unique pathways , G16H 20/10 ( 2006.01 ) identifying unique druggable targets for each stage .
    [Show full text]